The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib
Authors:
Open Access
- 28 November 2023
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 103 (2) , 427-436
Abstract
Patients with chronic myeloid leukemia (CML) treated with nilotinib or ponatinib may experience arterial occlusive events (AOEs). It is currently recommended to thoroughly assess cardiovascular risk factors before treating CML. We identified 455 consecutive CML adult patients, 335 treated with nilotinib and 120 with ponatinib; 380 patients without previous cardiovascular diseases or diabetes were stratified according to the Systematic Coronary Risk Evaluation (SCORE2) and SCORE2-Older Persons (SCORE2-OP). This updated algorithm from the European Society of Cardiology (ESC) estimates a 10-year risk of fatal and non-fatal cardiovascular diseases. It is based on sex, age, smoking habits, systolic blood pressure, non-high-density lipoprotein cholesterol, and European geographical region of cardiovascular risk. The SCORE2/SCORE2-OP algorithm translated more patients (50.2%) to the high–very high cardiovascular risk category than the previous SCORE (25.3%). Patients with a high to very high SCORE2/SCORE2-OP risk showed a significantly higher incidence rate of AOEs (69.2% vs. 46.5%, p < 0.001). The older SCORE was less specific in estimating AOEs in patients classified as low-intermediate risk (69.8 vs. 54.2%). In multivariate analysis, no associations were found between AOEs and gender, age, and type or dose of tyrosine kinase inhibitor. Only the SCORE2/SCORE2-OP risk was confirmed as a significant predictive factor (p = 0.028; hazard ratio = 2.2; 95% confidence interval = 1.1–4.5). Patients with AOEs required, in most cases, imaging diagnostic tests, additional drugs, and sometimes invasive procedures, increasing access to visits and hospital management. This real-life study suggested that the SCORE2 and SCORE2-OP charts could help identify cardiovascular fragility in CML patients providing them with more attention and a proper TKI selection.Keywords
Funding Information
- University of Cagliari
This publication has 31 references indexed in Scilit:
- Ponatinib in the therapy of chronic myeloid leukemiaExpert Review of Hematology, 2016
- Impact of dose intensity of ponatinib on selected adverse events: Multivariate analyses from a pooled population of clinical trial patientsLeukemia Research, 2016
- Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General PopulationJournal of Clinical Oncology, 2016
- Cardiovascular Events Associated With Use of Tyrosine Kinase Inhibitors in Chronic Myeloid LeukemiaAnnals of Internal Medicine, 2016
- Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall SurvivalJAMA Oncology, 2016
- Usefulness of the 2012 European CVD risk assessment model to identify patients at high risk of cardiovascular events during nilotinib therapy in chronic myeloid leukemiaLeukemia, 2014
- Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatmentAnnals of Hematology, 2014
- European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)Revista Portuguesa de Cardiologia (English Edition), 2013
- Linee guida europee sulla prevenzione delle malattie cardiovascolari nella pratica clinica (versione 2012). Quinta Task Force congiunta della Società Europea di Cardiologia e di altre Società sulla Prevenzione delle Malattie Cardiovascolari nella Pratica Clinica (costituita da rappresentanti di nove società e da esperti invitati)Giornale Italiano di Cardiologia, 2013
- Standardized definitions of molecular response in chronic myeloid leukemiaLeukemia, 2012